Know Cancer

or
forgot password

NK Activity Modulation by Intravenous Lidocaine During Laparoscopic Colorectal Surgery


Phase 4
18 Years
80 Years
Open (Enrolling)
Both
Colorectal Cancer

Thank you

Trial Information

NK Activity Modulation by Intravenous Lidocaine During Laparoscopic Colorectal Surgery


Inclusion Criteria:



- Patients admitted for resection of colorectal cancer under laparoscopic surgery

- American Society of Anesthesiologists class I-III.

- The subject is able to understand the study objectives, the experimental protocol and
procedures, and is capable of providing an informed consent.

Exclusion Criteria:

- Subjects allergic to any of the study drugs.

- BMI > 35 kg/m2.

- Severe renal or hepatic failure.

- Pregnancy.

- Emergent procedure.

- Heart failure NYHA > III.

- Systolic blood pressure < 90 mmHg.

- Advanced heart block (unless patient has a pacemaker).

- Unstable angina and/or myocardial infarction within past 6 weeks.

- FEV1 ≤ 0.8 L.

- Oxygen-dependent patient.

- Electrocardiographic abnormalities

- Treatment with immunosupressive drugs, corticosteroids, NSAIDS, antiarythmic

- Morphine intolerance or allergy

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science

Outcome Measure:

Dosage of NKs activity after surgery

Outcome Description:

Dosage of NKs activity after surgery

Outcome Time Frame:

compare the activity of NK cells on day 1 and day 3 after surgery

Safety Issue:

No

Principal Investigator

Louis-Philippe Fortier, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Hôpital Maisonneuve Rosemont

Authority:

Canada: Health Canada

Study ID:

11077

NCT ID:

NCT01841294

Start Date:

January 2012

Completion Date:

December 2013

Related Keywords:

  • Colorectal Cancer
  • Colorectal Neoplasms

Name

Location